

Dr. D. Y. Patil Pratishthan's

Dr. D. Y. PATIL COLLEGE OF PHARMACY

Dr. D. Y. Patil Educational Complex, Sector - 29, Pradhikaran, Akurdi, Pune 411 044.

Tel.: 020-27656141, Tel. Fax: 020-27656141

E-mail: info⊚dyppharmaakurdi.ac.in Web: www.dyppharmaakurdi.ac.in

Approved by: All India Council for Techinical Education, New Delhi

Pharmacy Council of India, New Delhi. Recognized by: Government of Maharashtra

Affiliated to Savitribai Phule Pune University, Pune

Dr. Sanjay D. Patil President Padmashree Dr. D. Y. Patil Founder

Shri. Satej D. Patil Vce-President & Chairman

Ref. No. : DYPCOP/

Date:

Dr. N. S. Vyawahare Principal

> 3.2.2 Summary of the Cover Page, Content Page & First Page of the Publication Indicating ISBN

Number and Year of Publication for Books & Chapters AY 2023-2024

:

Regd. Office: 2126E, "Ajinkyatara", Tarabai Park, Kolhapur - 416 003. Tel. No.: 0231-2653288/89/90 Fax No.: 0231-2653426

3.2.2 Summary of book/ book chapter published per teacher for 2023-24

Sr.no.	Name of Teacher	Number of book / book chapter Published	Year of publication	ISBN number of the book, book chapter and proceeding	Total no. of book/ book chapter published
1	Mrs. Bhavana Kapse	01	2023	978148044339	
2	Dr. Smita Sadar	01	2023	9786206770787	04
3	Dr.V.R.Vaidya, Dr.S.V.Pandya	01	2023	9788119117598	
4	Dr.P.M.Chaudhari	01	2023	978-981-5079-99- 9	

3.2.2 Summary of book/ book chapter published per teacher for 2023-24

Sr no	Title of Book/Book Chapter	Name of the Author	Year of Publication
1	<u>Pharmacotherapeutics</u>	Mrs. Bhavana Kapse	2023
2	Pathophysiology note	Dr. Smita Sadar	2023
3	Perspectives of Different Validation and Calibration Techniques	Dr.V.R.Vaidya, Dr.S.V.Pandya	2023
4	Recent Advances of Multifunctional Nanomedicine	Dr.P.M.Chaudhari	2023



Pharmacotherapeutics



Jyoti V. Chaudhari Sandhya R. Lanke Bhavana P. Kapse





PHARMACY COUNCIL OF INDIA

D. Pharmacy



Jyoti V. Chaudhari

M.Pharm (Pharmaceutics),
Assistant Professor, Department of Pharmaceutics,
SJVPM's Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research,
Chinchwad, Pune

Sandhya R. Lanke

M.Pharm (Pharmaceutics), Lecturer, Department of Pharmaceutics, SJVPM's Rosiklol M. Dhariwal College of Pharmacy, Chinchwad, Pune

Bhavana P. Kapse

M.Pharm (Pharmaceutics), Vice-Principal, Dr. D. Y. Patil Institute of Pharmacy, Akurdi, Pune



TABLE OF CONTENTS

Chapter - 1 Introduction to Pharmacotherapeutics	(1 - 1) to (1 - 16)
duation	***************************************
1.1 Introduction	-1-γ
1.3 Objectives	1.5
1.3 Objectives	1.5
1.4 Rational use of Medicines	1-5
1.5 Evidence Based Medicine	1-8
1.6 Essential Medicines List	1-11
1.7 Standard Treatment Guidelines (STGs)	1 - 13
Fill in the Blanks	
Questions	1 - 15
Chapter - 2 Cardiovascular System Diseases	(2 - 1) to (2 - 20)
2.1 Introduction	
2.2 Cardiovascular Diseases (CVDs)	2-3
2.2.1 Anatomy of Heart	2-3
2.3 Hypertension	
2.3.1 Clinical Manifestations of Hypertension	2-6
2.3.2 Etiopathogenesis	2-6
2.3.3 Diagnosis	2-3
2.3.4 Non-Pharmacological Management of Hypertension	
2.3.5 Pharmacological Management of Hypertension	
2.4 Angina	
2.4.1 Signs and Symptoms of Angina Pectoris	
2.4.2 Etiopathogenesis	
2.4.3 Pathophysiology of Angina Pectoris	2 - 11
2.4.4 Diagnosis	2 - 11
2.4.5 Non-Pharmacological Management of Angina Pectori	2 - 11
2.4.6 Pharmacological Management of Angina Pectoris	2-11

2.5.1 Signs and Symptoms of Myocardial Infarctions 2 - 14 2.5.2 Etiopathogenesis of Myocardial Infarctions 2 - 14 2.5.3 Diagnosis 2 - 15 2.5.4 Non-Pharmacological Management of Myocardial Infarction 2 - 15 2.5.5 Pharmacological Management of Myocardial Infarction 2 - 15 2.6 Hyperlipidemia 2 - 15 2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2.2 Etiopathogenesis 3 - 4		2.5 Myocardial Infarction	2 - 12
2.5.3 Diagnosis 2 - 15 2.5.4 Non-Pharmacological Management of Myocardial Infarction 2 - 15 2.5.5 Pharmacological Management of Myocardial Infarction 2 - 15 2.6 Hyperlipidemia 2 - 15 2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2.2 Etiopathogenesis 3 - 3 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Phar		2.5.1 Signs and Symptoms of Myocardial Infarctions	2 - 14
2.5.4 Non-Pharmacological Management of Myocardial Infarction 2 - 15 2.5.5 Pharmacological Management of Myocardial Infarction 2 - 15 2.6 Hyperlipidemia 2 - 15 2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6 4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2.2 Etiopathogenesis 3 - 3 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7		2.5.2 Etiopathogenesis of Myocardial Infarctions	2 - 14
2.5.5 Pharmacological Management of Myocardial Infarction 2 - 15 2.6 Hyperlipidemia 2 - 15 2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3.1 Non-Pharmac		2.5.3 Diagnosis	2 - 15
2.6 Hyperlipidemia 2 - 15 2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3.1 Non-Pharmacological Management 3 - 14 Multiple Choice Questions with Answers		2.5.4 Non-Pharmacological Management of Myocardial Infarct	ion2 - 15
2.6.1 Signs and Symptoms of Hyperlipidemia 2 - 16 2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management		2.5.5 Pharmacological Management of Myocardial Infarction	2 - 15
2.6.2 Etiopathogenesis of Hyperlipidemia 2 - 16 2.6.3 Non-Pharmacological Management of Hyperlipidemia 2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3.1 Non-Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14 Multiple Choice Questions with Answers <		2.6 Hyperlipidemia	2 - 15
2.6.3 Non-Pharmacological Management of Hyperlipidemia .2 - 16 2.6.4 Pharmacological Management of Hyperlipidemia .2 - 16 2.7 Congestive Heart Failure .2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure .2 - 17 2.7.2 Signs and Symptoms of Heart Failure .2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure .2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure .2 - 18 2.8 Prevention of CVDs .2 - 18 Multiple Choice Questions with Answers .2 - 19 Questions .2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction .3 - 2 3.2 Asthma .3 - 2 3.2.1 Clinical Manifestations .3 - 3 3.2.2 Etiopathogenesis .3 - 4 3.2.3 Diagnosis and Investigation .3 - 5 3.2.4 Non Pharmacological Management of Asthma .3 - 7 3.2.5 Pharmacological Management of Asthma .3 - 7 3.3 Chronic Obstructive Pulmonary Disease .3 - 10 3.3.1 Non-Pharmacological Management .3 - 14 Multiple Choice Questions with Answers .3 - 14		2.6.1 Signs and Symptoms of Hyperlipidemia	2 - 16
2.6.4 Pharmacological Management of Hyperlipidemia 2 - 16 2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2 Etiopathogenesis 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 3 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 10 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.6.2 Etiopathogenesis of Hyperlipidemia	2 - 16
2.7 Congestive Heart Failure 2 - 17 2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.6.3 Non-Pharmacological Management of Hyperlipidemia	2 - 16
2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.6.4 Pharmacological Management of Hyperlipidemia	2 - 16
2.7.1 Etiopathogenesis of Congestive Heart Failure 2 - 17 2.7.2 Signs and Symptoms of Heart Failure 2 - 18 2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.7 Congestive Heart Failure	2 - 17
2.7.3 Non-Pharmacological Management Congestive Heart Failure 2 - 18 2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.3.2 Pharmacological Management 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14			
2.7.4 Pharmacological Management Congestive Heart Failure 2 - 18 2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.7.2 Signs and Symptoms of Heart Failure	2 - 18
2.8 Prevention of CVDs 2 - 18 Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.7.3 Non-Pharmacological Management Congestive Heart Fail	lure2 - 18
Multiple Choice Questions with Answers 2 - 19 Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.7.4 Pharmacological Management Congestive Heart Failure.	2 - 18
Questions 2 - 20 Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		2.8 Prevention of CVDs	2 - 18
Chapter - 3 Respiratory System Diseases (3 - 1) to (3 - 16) 3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		Multiple Choice Questions with Answers	2 - 19
3.1 Introduction 3 - 2 3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		Questions	2 - 20
3.2 Asthma 3 - 2 3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14	Ch	apter - 3 Respiratory System Diseases	(3 - 1) to (3 - 16)
3.2.1 Clinical Manifestations 3 - 3 3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.1 Introduction	3 - 2
3.2.2 Etiopathogenesis 3 - 4 3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.2 Asthma	3 - 2
3.2.3 Diagnosis and Investigation 3 - 5 3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.2.1 Clinical Manifestations	3 - 3
3.2.4 Non Pharmacological Management of Asthma 3 - 7 3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.2.2 Etiopathogenesis	3 - 4
3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.2.3 Diagnosis and Investigation	3 - 5
3.2.5 Pharmacological Management of Asthma 3 - 7 3.3 Chronic Obstructive Pulmonary Disease 3 - 10 3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.2.4 Non Pharmacological Management of Asthma	3 - 7
3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14			
3.3.1 Non-Pharmacological Management 3 - 13 3.3.2 Pharmacological Management 3 - 14 Multiple Choice Questions with Answers 3 - 14		3.3 Chronic Obstructive Pulmonary Disease	3 - 10
3.3.2 Pharmacological Management			
Multiple Choice Questions with Answers			
Questions			
		Questions	3 - 15



Jyoti V. Chaudhari is currently working as a Assistant Professor at SJVPM's Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune. She formerly worked at JSPM's Jayawant Institute of Pharmacy, Tathawade, Pune. She is approved faculty by Maharashtra State Board of Technical Education (MSBTE), Mumbai since October 2012. Her post-graduation is from Sanjeevan College of Pharmacy, Dausa (RUHS), Rajasthan. She is graduated from NDMVP's College of Pharmacy, Nasik. She has more than 18 years of teaching and industrial experience. She has FDA approval in chemical and instrumental analysis. She has contributed as paper setter of Maharashtra Knowledge Corporation Ltd. for Govt. Pharmacist Recruitment Examination. She has 4 paper publications to her credit and has invited as jury in various MSBTE and Indian Pharmaceutical Association intercollege technical and non-technical competitions. She is active member of various committees of the MSBTE, Mumbai. She has attended various MSBTE, AlCTE and APTI sponsored National and International Conferences, Industrial trainings, Induction programs, Seminars and workshops. She believes in continuous learning approach and contributing in professional and personal development of students.




Sandhya R. Lanke is currently working as a Lecturer at SJVPM's Rasikial M. Dhariwal College of Pharmacy, Chinchwad, Pune. She is approved faculty by Maharashtra State Board of Technical Education (MSBTE), Mumbal since October 2012. She has 14 years of teaching and one year of industrial experience. She is graduated from SCSSS's Sitabal Thite College of Pharmacy, Shirur. Her post-graduation is from Sanjeevan College of Pharmacy, Dausa (RUHS), Rajasthan. She has 5 paper publications to her credit. She is a lifetime member of Association of Pharmaceutical Teachers of India (APTI). She has attended various MSBTE, AICTE and APTI sponsored National and International Industrial trainings, Induction Programs, Conferences, Seminars and the students for being technically competent professional and healthcare provider.



Shavana A. Wani (Mrs. Bhavana P. Kapse) has completed her D. Pharm, was topper from Y.B. Chavan College of Pharmacy, Aurangabad. She has completed her B. Pharm with Distinction, University topper in all the three years in Dr. Babasaheb Ambedkar Marathwada University, Aurangabad. She was awarded Gold medal from Government College of Pharmacy. She is pursuing her Ph.D. under Savitribai Phule Pune University, Pune. She is Currently working as Vice-Principal, HOD, Academic Coordinator and Training and Placement Officer at Dr.D.Y.Patil Institute of Pharmacy, Akurdi, Pune. She has done M.Pharm (Pharmaceutics). She has 16 years experience. She has attended about 28 Seminars, Workshop, FDP and Conferences and presented Posters in different conferences. She was Program Coordinator for One Day State Level Quiz Competition sponsored by MSBTE and received a grant of Rs 103000/- on her credit. In 2014-15 she was awarded as Best Teacher award by her institute. She has been a Jury member for MSBTE sponsored State Level Paper Presentation

award by her institute. She has been a Jury member for MSBTE sponsored State Level Paper Presentation competition organized at Rasiklal Dhariwal College of Pharmacy. She also worked as a member in MSBTE activity like Academic Monitoring Committee, RRAC and Exam Controller. Her areas of interest include Novel Drug Delivery System. She is life member of Association of Pharmaceutical Teachers of India (APTI).

Available at all leading booksellers













Website: www.technicalpublications.in f https://www.facebook.com/technicalpublicat

Arnit Residency, Office No.1, 412, Shariwar Peth, Pune - 411030, M.S. I Ph.: +91-020-24495496/97, | Email : info@technicalpublication

Pathophysiology Notes

Welcome to the "Pathophysiology Notes," an exclusive guide tailored for Bachelor of Pharmacy (B. Pharmacy) students. Pathophysiology stands as a pivotal discipline delving into the fundamental mechanisms of diseases, laying the groundwork for understanding how deviations from normal bodily functions contribute to various health conditions. This guide has been meticulously curated to accompany your academic journey, providing a clear and concise explanation of intricate pathophysiological concepts. With a focus on clarity and relevance, these notes aim to simplify complex ideas, aiding in your grasp of fundamental principles effortlessly. For B. Pharmacy students, mastering pathophysiology holds immense importance in comprehending the mechanisms of action of drugs, their therapeutic effects, and adverse reactions. It forms the cornerstone of your understanding in pharmacology, therapeutics, and clinical pharmacy, equipping you with a robust framework to excel in academic pursuits and future professional endeavours.

Edited By Dr. Aniket Garud

Nahata, Warude, Sadar

Mr. Anuj N. Nahata - Scholar SVKMs NMIMS-Deemed to be a University.

Miss. Shivani V. Nahar - Scholar RMDIPER.

Mrs. Bhagyashri Warude - Ass. Prof. School of Pharmacy D.Y. Patil University.

Dr. Smita Sadar - Associate Prof. D.Y. Patil College of Pharmacy.

Editor

Dr. Aniket Garud - Ass. Prof. RMDIPER.



Scholars' Press Anuj Nahata & Shivani Nahar Bhagyashri Warude Dr. Smita Sadar **Pathophysiology Notes** Edited by Dr. Aniket Garud

Index

Sr. No	Chapter	Page No
1.	Basic principles of Cell injury and Adaptation	1
2.	Basic mechanism involved in the process of inflammation and repair	35
3.	Cardio vascular System	59
4.	Respiratory system	101
5.	Renal system	119
6.	Haematological Diseases	129
7.	Endocrine system	176
8.	Nervous system	267
9.	Gastrointestinal system	357
10.	Diseases of bones and joints	407
11.	Cancer	438
12.	Infectious diseases	450
13.	Sexually transmitted diseases	517



ABOUT THE AUTHORS



Or. Vishal D. Yadav is presently working as Associate Professor and Head in Department of Pharmaceutics, at Arvind Gavali College of Pharmacy Jaitapur, Satara. He has overall 16 years of teaching, administrative, research and industrial experience. He has 04 granted patents on his credit. He has published 01 book and 40 research papers in various National and International peer reviewed journals. He has guided 28 PG students. He has delivered 02 expert lectures. He has provided consultancy to pharmaceutical industries. He has completed his UG from Satara College of Pharmacy, Shivaji

University Kolhapur, PG from Annamalai University, Chidambaram and Ph.D. from VELS University, Chennai. His area of research interests includes Pelletization techniques, Multi particulates for anticancer drugs, Validation techniques.



Dr. Vaibhav R. Vaidya is presently working as Associate Professor, Department of Pharmaceutics, at Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune. He has overall 15 years of teaching, administrative, research and industrial experience. He has published/03Indian patents He has authored14 research and review papers in various National and International journals. He has guided 20 PG students: He has delivered 04 expert lectures. He has provided consultancy to pharmaceutical industries. He has completed his PG from RGUHS, Bangalore and Ph.D. from JNTU, Hyderabad. His area of research

includes dermatology formulations, solubility improvement studies and novel drug delivery systems.



Dr. Sudhir V. Pandya is presently working as Professor, Department of Pharmaceutics, at Dr. D. Y. Patti College of Pharmacy, Akurdi, Pune. He has overall 34 years of Industrial and 04 years of teaching, administrative, research experience. He is working committee member for Indian Pharmacopoeia Commission. He has also conducted Pre-Inspection Audits for various pharmaceutical companies. He has published 08 research and review papers in various National and International journals. He has delivered 58 expert lectures in various colleges and scientific forums. He has provided consultancy

to pharmaceutical industries. He has completed his PG from Singhania University, Rajasthan and Ph.D. from Bundelkhand University. His core competency is in quality assurance, analytical method development, regulatory affairs, formulation development and pharmaceutical audits.









AS PER PCI REGULATIONS B. PHARM. and M. PHARM.

PERSPECTIVES OF DIFFERENT VALIDATION AND CALIBRATION TECHNIQUES


Dr. VISHAL D. YADAV Dr. VAIBHAV R. VAIDYA Dr. SUDHIR V. PANDYA













View SampleDownload Sample

Editor: Priya Patel

Role of Nanotechnology in Cancer Therapy

eBook: US \$79 Special Offer (PDF + Printed Copy): US \$136 Printed Copy: US \$96 Library License: US \$316 ISBN: 978-981-5080-00-1 (Print) ISBN: 978-981-5079-99-9 (Online) Vear of Publication: 2023 DOI: 10.2174/97898150799991230101

Rate This Book Introduction

Role of Nanotechnology in Cancer Therapy gives an overview of the innovative nanocarrier-based approaches for managing various cancers such as gastric, skin, lung, and prostate cancers. The book also explores the evolving targeting approaches specific to cancer and the immunotherapy-based nanomedicinal approach. Several drug-delivery systems which reduce the overall toxicity of cytotoxic drugs and increase their effectiveness and selectivity are also discussed in this book.

Key features:

- Discusses the potential benefits and therapeutic applications of nanoparticles in cancer management
- Provides information about therapy in a range of cancers
 Discusses recent developments in cancer nanomedicine including targeted therapy, immonotherapy nanoparticles and dual drug delivery
 Includes safety and toxicity considerations
- · Provides references for advanced readers

This book will inform a broad range of readers including undergraduate and postgraduate students, oncologists, pharmacists, and researchers involved in nanomedicine and nano-drug delivery about current advancement in cancer nanomedicine.

Audience: undergraduate and postgraduate students, oncologists, pharmacists, and researchers involved in nanomedicine and nano-drug delivery about current advancement in cancer nanomedicine.

Indexed in: Scopus.

eBook: US \$79 Special Offer: US \$136 Printed Copy: US \$96 Library License: US \$316

Foreword - Pp. i

Pranay Shah Download Free

Preface - Pp. ii-iii (2) Priya Patel Download Free

List of Contributors - Pp. iv-v (2)

Download Free

Cancer Pathophysiology - Pp. 1-23 (23) Devang B. Sheth*, Chirag A. Patel, Sandip B. Patel

PDF Price: \$30


View Abstract Purchase Chapter

Recent Advances of Multifunctional Nanomedicine - Pp. 24-38 (15)

Pallavi M Chaudhari*

https://benthambooks.com/book/9789815079999/#.~:text=Role of Nanotechnology in Cancer Therapy gives an overview of,the immunotherapy-b...

5/7



24

Role of Nanotechnology in Cancer Therapy, 2023, 24-38

CHAPTER 2

Recent Advances of Multifunctional Nanomedicine

Pallavi M. Chaudharita

Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune- 411044, India

Abstract: The revolution of nanomedicine has emerged as an array of biological products in the pharmaceutical field. Their peculiarity of nanosize has been a benefit for the detection and prevention of diseases by application of engineered nanodevices and nanostructures. This presents range of opportunities, that are suitable for most drugs, prevents side effects, and enhances patient compliance. Nanomedicine has fascinated medical research in developing different multifunctional nanostructures like dendrimers, nanoparticles, micelles, quantum dots, carbon nanotubes, etc. However, there are still certain impedes to bringing out the best amongst these nanomedicines. This chapter will spotlight the recent advances of multifunctional nanomodicine, solely to combat cancer disease conditions, that can offer improvement in the pharmacokinetic and pharmacodynamic profiles of the conventional approaches and optimize the efficacy of the existing anticancer drugs. In recent years, combination therapy has also shown good improvement in cancer therapy as compared to monotherapy. The theranostic application can offer a good alternative to cancer treatment. So, when the insights are combined with new nanotechnology-based therapy, targeted drug delivery can be obtained to avoid the side effects, but the concern of their toxicity should also be noted. Hence, nanomedicine represents one of the advanced fields that combine nanotechnology and medicine for improved efficiency and safety to human health, through the study of elucidation of cellular and molecular mechanisms, to design performant nano-delivery as an efficient tool for the treatment of cancer. Thus, the exploration of the properties needs to be understood to execute the unmet needs and attain project cost benefits.